Unknown

Dataset Information

0

Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate.

ABSTRACT: Loss of imprinting (LOI) is an epigenetic alteration involving loss of parental origin-specific expression at normally imprinted genes. A LOI for Igf2, a paracrine growth factor, is important in cancer progression. Epigenetic modifications may be altered by environmental factors. However, is not known whether changes in imprinting occur with aging in prostate and other tissues susceptible to cancer development. We found a LOI for Igf2 occurs specifically in the mouse prostate associated with increased Igf2 expression during aging. In older animals, expression of the chromatin insulator protein CTCF and its binding to the Igf2-H19 imprint control region was reduced. Forced down-regulation of CTCF leads to Igf2 LOI. We further show that Igf2 LOI occurs with aging in histologically normal human prostate tissues and that this epigenetic alteration was more extensive in men with associated cancer. This finding may contribute to a postulated field of cancer susceptibility that occurs with aging. Moreover, Igf2 LOI may serve as a marker for the presence of prostate cancer.

SUBMITTER: Fu VX 

PROVIDER: S-EPMC4237281 | biostudies-literature | 2008 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate.

Fu Vivian X VX   Dobosy Joseph R JR   Desotelle Joshua A JA   Almassi Nima N   Ewald Jonathan A JA   Srinivasan Rajini R   Berres Mark M   Svaren John J   Weindruch Richard R   Jarrard David F DF  

Cancer research 20080801 16

Loss of imprinting (LOI) is an epigenetic alteration involving loss of parental origin-specific expression at normally imprinted genes. A LOI for Igf2, a paracrine growth factor, is important in cancer progression. Epigenetic modifications may be altered by environmental factors. However, is not known whether changes in imprinting occur with aging in prostate and other tissues susceptible to cancer development. We found a LOI for Igf2 occurs specifically in the mouse prostate associated with inc  ...[more]

Similar Datasets

Unknown Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer.
| S-EPMC3825178 | biostudies-literature
Unknown Reduced Insulin-Like Growth Factor-I Effects in the Basal Forebrain of Aging Mouse.
| S-EPMC8442768 | biostudies-literature
Unknown A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-κB activation.
| S-EPMC3928145 | biostudies-literature
Unknown Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer.
| S-EPMC8763370 | biostudies-literature
Unknown Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function.
| S-EPMC2941281 | biostudies-literature
Unknown Loss of insulin-like growth factor II imprinting is a hallmark associated with enhanced chemo/radiotherapy resistance in cancer stem cells.
| S-EPMC5239480 | biostudies-literature
Unknown Loss of imprinting of a paternally expressed transcript, with antisense orientation to KVLQT1, occurs frequently in Beckwith-Wiedemann syndrome and is independent of insulin-like growth factor II imprinting.
| S-EPMC21842 | biostudies-literature
Unknown Insulin-like growth factor-1 in CNS and cerebrovascular aging.
| S-EPMC3698444 | biostudies-literature
Unknown Insulin-Like Growth Factor I Prevents Cellular Aging via Activation of Mitophagy.
| S-EPMC7416301 | biostudies-literature
Unknown Insulin-like growth factor-I induces chemoresistence to docetaxel by inhibiting miR-143 in human prostate cancer.
| S-EPMC5739804 | biostudies-literature